当前位置: 首页 >> 检索结果
83. Evaluation of post-market adverse events of lubiprostone: a real-world adverse event analysis from the FAERS database.
作者: Qingqing Li.;Jijun Zhang.;Chuanli Yang.;Xiushan Dong.;Yan Wang.
来源: BMC Gastroenterol. 2025年25卷1期395页
Lubiprostone is a selective intestinal chloride channel activator approved for treating chronic idiopathic constipation and constipation-predominant irritable bowel syndrome in adults. However, real-world data on its long-term safety, particularly regarding adverse events necessitating ongoing supplementation, remain limited.
84. Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.
作者: Farzad Salmanizadeh.;Sakineh Sabzevari.;Sara Shafieipour.;Mohammad Javad Zahedi.;Afshin Sarafinejad.
来源: BMC Gastroenterol. 2025年25卷1期396页
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and it poses a significant threat to public health. There is insufficient documented evidence about the problems and needs of patients and physicians in managing NAFLD. This study aimed to explore the challenges and needs in managing NAFLD from the perspective of gastroenterology and hepatology (GH) specialists.
85. Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.
The study mainly aim at exploring the ascites risk factors among decompensated cirrhosis patients via constructing the prediction model of ascites incidence.
90. Association between proteinuria changes and colorectal cancer incidence: evidence from a nationwide cohort study.
The presence of excess proteins in the urine, known as proteinuria, has been linked to various health conditions, including chronic kidney disease and cancer. Emerging evidence suggests an association between proteinuria and colorectal cancer, a leading global cause of cancer-related morbidity and mortality. However, the impact of changes in proteinuria status on colorectal cancer risk remains unclear. Understanding this relationship may identify proteinuria as a modifiable risk factor for colorectal cancer prevention.
91. Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver condition closely associated with metabolic syndrome and linked to circadian disruptions. Circadian Syndrome (CircS), a constellation of metabolic and circadian dysregulations, has emerged as a risk factor for metabolic disorders. This study aims to examine the association between CircS and MASLD and to evaluate the potential relevance of CircS in identifying individuals at elevated MASLD risk.
92. Effect of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum on the expression of genes related to colorectal cancer in colon adenocarcinoma (Caco-2) cell line.
作者: Rahimeh Maqsoodi.;Masoumeh Saberpour.;Bita Bakhshi.;Fatemeh Fallah.
来源: BMC Gastroenterol. 2025年25卷1期394页
Colorectal cancer (CRC) is emerged as a global problem with high mortality rate; hence, finding of alternative treatment approaches is essential. The purposes of this research are to assess the impact of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum (CTNP/B.b-sup) on genes associated with CRC signaling pathways.
93. The association between inflammatory biomarkers and gallstones in Americans under 50 years old.
作者: Shuqin Cheng.;Yaping Zhang.;Lu Jiang.;Jiana Li.;Runci Jiang.;Fengmei Wang.
来源: BMC Gastroenterol. 2025年25卷1期393页
This study aimed to assess the link between inflammatory biomarkers (like the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammatory index (SII), and systemic inflammation response index (SIRI)) and gallstones in American individuals aged under 50 years.
94. Initial development and validation of a disease-specific resilience measure for inflammatory bowel disease: the RISE-IBD instrument.
作者: Michelle Mendiolaza.;Camila Vicioso.;Wamia Siddiqui.;Karan Lingineni.;Ksenia Gorbenko.;Parul Agarwal.;Laurie Keefer.
来源: BMC Gastroenterol. 2025年25卷1期390页
Inflammatory bowel diseases (IBDs) have a substantial effect on the well-being and quality of life of patients. While resilience may help alleviate psychological and physical burdens in individuals with IBD, there is no disease-specific measure that currently exists to accurately quantify this construct in the context of IBD. This study aimed to psychometrically validate the new Resilience Scale for IBD (RISE-IBD).
95. Development of Acute Kidney Injury in a Patient With Alcohol-related Cirrhosis: The Importance of Diagnosing the Cause of Acute Kidney Injury.
作者: Adrià Juanola.;Ann T Ma.;Giuseppe Cullaro.;Mariam P Alexander.;Andrew S Allegretti.;Pere Ginès.
来源: Gastroenterology. 2025年 96. Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition.
作者: Sophie Irwin.;Mieke van Daelen.;Isabella Almaraz.;Rebecca Park.;Becca Nelson.;Swapna Mahurkar-Joshi.;Florian Rieder.;David Q Shih.;Wendy Ho.;Berkeley Limketkai.;Hon Wai Koon.
来源: Gastroenterology. 2025年
About 30%-50% of patients with Crohn's disease (CD) eventually develop intestinal strictures, with intestinal fibrosis being a major component of them. There is currently no approved medication to treat fibrotic strictures.
97. Association between celiac disease and risk of kidney diseases: a systematic review and meta-analysis.
作者: Sawai S Rathore.;Shifa P Shaikh.;Hyder R Zaidi.;George O Salako.;Chiranjeevee R Saravanan.;Rabiat R Kuranga.;Narendra Yagateela.;Sai T Bandala.;Bijay M Jeswani.
来源: Minerva Gastroenterol (Torino). 2025年
Celiac disease (CD), an autoimmune disorder, has been linked to chronic kidney disease but results are inconsistent. This meta-analysis investigates the association between CD and the risk of kidney disease.
98. Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas.
作者: Zhijuan Wu.;Min Zhang.;Ruirui Tian.;Jibing Liu.;Xu Chang.;Shangkun Ning.;Yingli Yu.;Lin Zhang.
来源: BMC Gastroenterol. 2025年25卷1期387页
The present study aimed to evaluate the effectiveness of spring coils or gelatin sponges for the embolization of giant hepatocellular carcinoma (HCC) with a hepatic arterioportal shunt (APS) in targeted therapy.
99. Worldwide burden and cross-regional health inequalities of high BMI-attributable colorectal cancer by gender from 1990 to 2021, with predictions through 2041.
To analyze the worldwide, regional, and national burden and trends of colorectal cancer (CRC) attributable to high body mass index (BMI) by gender from 1990 to 2021 and to forecast the burden through 2041.
100. Better diagnostic accuracy for GERD observed with the new MNBI cutoff: an observational study in Vietnam.
作者: Hang Dao Viet.;Hue Luu Thi Minh.;Long Hoang Bao.;Phuong Do Nhat.;Long Dao Van.
来源: BMC Gastroenterol. 2025年25卷1期388页
Mean nocturnal baseline impedance (MNBI) is a novel metric for multichannel ambulatory impedance and pH (MI-pH) monitoring used to diagnose gastroesophageal reflux disease (GERD); however, its thresholds vary among different geographic areas and measuring systems. This study analyzed MI-pH data from Vietnamese patients to assess the diagnostic utility of novel MNBI thresholds in identifying GERD.
|